Gene Set Signature of Reversal Reaction Type I in Leprosy Patients

PLoS Genetics

Volumn 9, Issue 7, 2013, Pages

  Orlova, Marianna ^a   Cobat, Aurélie ^a,b   Huong, Nguyen Thu ^c   Ba, Nguyen Ngoc ^c   Van Thuc, Nguyen ^c   Spencer, John ^d   Nédélec, Yohann ^e   Barreiro, Luis ^e   Thai, Vu Hong ^c   Abel, Laurent ^f,g,h   Alcaïs, Alexandre ^f,g,h,i   Schurr, Erwin ^a,b  

^a RESEARCH INSTITUTE OF THE MCGILL UNIVERSITY HEALTH CENTRE   (Canada)

^b MCGILL UNIVERSITY   (Canada)

^c Hospital for Dermato Venereology   (Viet Nam)

^d Veterinary Dentistry and Oral Surgery   (United States)

^e UNIVERSITY OF MONTREAL   (Canada)

^f IMAGINE INSTITUTE   (France)

^g UNIVERSITÉ PARIS DESCARTES   (France)

^h ROCKEFELLER UNIVERSITY   (United States)

ⁱ Paris Descartes University   (France)

Author keywords

[No Author keywords available]

Indexed keywords

TRANSCRIPTOME;

ADOLESCENT; ADULT; ARACHIDONIC ACID METABOLISM; ARTICLE; CHILD; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; GENE EXPRESSION; GENE FUNCTION; GENE SET SIGNATURE; HUMAN; INFLAMMATION; INNATE IMMUNITY; LEPROSY; MALE; MOLECULAR GENETICS; MYCOBACTERIUM LEPRAE; NONHUMAN; PROSPECTIVE STUDY; RETROSPECTIVE STUDY; REVERSAL REACTION; REVERSAL REACTION TYPE 1; SCHOOL CHILD; VALIDITY;

ADOLESCENT; ADULT; ANTIGENS, BACTERIAL; CHILD; FEMALE; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; HUMANS; IMMUNITY, INNATE; INTERFERON-GAMMA; LEPROSY; MALE; MYCOBACTERIUM LEPRAE; NERVE DEGENERATION; RETROSPECTIVE STUDIES;

EID: 84880778953     PISSN: 15537390     EISSN: 15537404     Source Type: Journal    
DOI: 10.1371/journal.pgen.1003624     Document Type: Article

References (73)

1. WHO (2010) Global leprosy situation, 2010. Wkly Epidemiol Rec 85: 337-348.
2. Britton WJ, Lockwood DN, (2004) Leprosy. Lancet 363: 1209-1219.
3. Scollard DM, Adams LB, Gillis TP, Krahenbuhl JL, Truman RW, et al. (2006) The continuing challenges of leprosy. Clin Microbiol Rev 19: 338-381.
4. Ridley DS, Jopling WH, (1966) Classification of leprosy according to immunity. A five-group system. Int J Lepr Other Mycobact Dis 34: 255-273.
5. Fava V, Orlova M, Cobat A, Alcais A, Mira M, et al. (2012) Genetics of leprosy reactions: an overview. Mem Inst Oswaldo Cruz 107 (Suppl. I) (): 132-42.
6. Walker SL, Lockwood DN, (2007) Leprosy. Clin Dermatol 25: 165-172.
7. Kumar B, Dogra S, Kaur I, (2004) Epidemiological characteristics of leprosy reactions: 15 years experience from north India. Int J Lepr Other Mycobact Dis 72: 125-133.
8. Ranque B, Nguyen VT, Vu HT, Nguyen TH, Nguyen NB, et al. (2007) Age is an important risk factor for onset and sequelae of reversal reactions in Vietnamese patients with leprosy. Clin Infect Dis 44: 33-40.
9. Little D, Khanolkar-Young S, Coulthart A, Suneetha S, Lockwood DN, (2001) Immunohistochemical analysis of cellular infiltrate and gamma interferon, interleukin-12, and inducible nitric oxide synthase expression in leprosy type 1 (reversal) reactions before and during prednisolone treatment. Infect Immun 69: 3413-3417.
10. Rose P, Waters MF, (1991) Reversal reactions in leprosy and their management. Lepr Rev 62: 113-121.
11. Verhagen CE, Wierenga EA, Buffing AA, Chand MA, Faber WR, et al. (1997) Reversal reaction in borderline leprosy is associated with a polarized shift to type 1-like Mycobacterium leprae T cell reactivity in lesional skin: a follow-up study. J Immunol 159: 4474-4483.
12. Stefani MM, Martelli CM, Gillis TP, Krahenbuhl JL, (2003) In situ type 1 cytokine gene expression and mechanisms associated with early leprosy progression. J Infect Dis 188: 1024-1031.
13. Moraes MO, Sarno EN, Almeida AS, Saraiva BC, Nery JA, et al. (1999) Cytokine mRNA expression in leprosy: a possible role for interferon-gamma and interleukin-12 in reactions (RR and ENL). Scand J Immunol 50: 541-549.
14. Moraes MO, Sampaio EP, Nery JA, Saraiva BC, Alvarenga FB, et al. (2001) Sequential erythema nodosum leprosum and reversal reaction with similar lesional cytokine mRNA patterns in a borderline leprosy patient. Br J Dermatol 144: 175-181.
15. Khanolkar-Young S, Rayment N, Brickell PM, Katz DR, Vinayakumar S, et al. (1995) Tumour necrosis factor-alpha (TNF-alpha) synthesis is associated with the skin and peripheral nerve pathology of leprosy reversal reactions. Clin Exp Immunol 99: 196-202.
16. Becx-Bleumink M, Berhe D, (1992) Occurrence of reactions, their diagnosis and management in leprosy patients treated with multidrug therapy; experience in the leprosy control program of the All Africa Leprosy and Rehabilitation Training Center (ALERT) in Ethiopia. Int J Lepr Other Mycobact Dis 60: 173-184.
17. van Brakel WH, Khawas IB, Lucas SB, (1994) Reactions in leprosy: an epidemiological study of 386 patients in west Nepal. Lepr Rev 65: 190-203.
18. Schreuder PA, (1998) The occurrence of reactions and impairments in leprosy: experience in the leprosy control program of three provinces in northeastern Thailand, 1987-1995 [correction of 1978-1995]. II. Reactions. Int J Lepr Other Mycobact Dis 66: 159-169.
19. Sharma N, Koranne RV, Mendiratta V, Sharma RC, (2004) A study of leprosy reactions in a tertiary hospital in Delhi. J Dermatol 31: 898-903.
20. Huang dW, Sherman BT, Lempicki RA, (2009) Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources. Nat Protoc 4: 44-57.
21. Dennis G Jr, Sherman BT, Hosack DA, Yang J, Gao W, et al. (2003) DAVID: Database for Annotation, Visualization, and Integrated Discovery. Genome Biol 4: R60.1-R60.11.
22. Ashburner M, Ball CA, Blake JA, Botstein D, Butler H, et al. (2000) Gene ontology: tool for the unification of biology. The Gene Ontology Consortium. Nat Genet 25: 25-29.
23. Lee HK, Braynen W, Keshav K, Pavlidis P, (2005) ErmineJ: tool for functional analysis of gene expression data sets. BMC Bioinformatics 6: 269-276.
24. Gillis J, Mistry M, Pavlidis P, (2010) Gene function analysis in complex data sets using ErmineJ. Nat Protoc 5: 1148-1159.
25. Britton WJ, (1998) The management of leprosy reversal reactions. Lepr Rev 69: 225-234.
26. Walker SL, Lockwood DN, (2008) Leprosy type 1 (reversal) reactions and their management. Lepr Rev 79: 372-386.
27. Cooper CL, Mueller C, Sinchaisri TA, Pirmez C, Chan J, et al. (1989) Analysis of naturally occurring delayed-type hypersensitivity reactions in leprosy by in situ hybridization. J Exp Med 169: 1565-1581.
28. Kirkaldy AA, Musonda AC, Khanolkhar-Young S, Suneetha S, Lockwood DN, (2003) Expression of CC and CXC chemokines and chemokine receptors in human leprosy skin lesions. Clin Exp Immunol 134: 447-453.
29. Pesce C, Grattarola M, Menini S, Fiallo P, (2006) Cyclooxygenase 2 expression in vessels and nerves in reversal reaction leprosy. Am J Trop Med Hyg 74: 1076-1077.
30. Mindrescu C, Le J, Wisniewski HG, Vilcek J, (2005) Up-regulation of cyclooxygenase-2 expression by TSG-6 protein in macrophage cell line. Biochem Biophys Res Commun 330: 737-745.
31. Kozak KR, Rowlinson SW, Marnett LJ, (2000) Oxygenation of the endocannabinoid, 2-arachidonylglycerol, to glyceryl prostaglandins by cyclooxygenase-2. J Biol Chem 275: 33744-33749.
32. Fournier T, Medjoubi N, Porquet D, (2000) Alpha-1-acid glycoprotein. Biochim Biophys Acta 1482: 157-171.
33. Gupta N, Shankernarayan NP, Dharmalingam K, (2010) alpha1-acid glycoprotein as a putative biomarker for monitoring the development of the type II reactional stage of leprosy. J Med Microbiol 59: 400-407.
34. Kupcova V, Turecky L, Detkova Z, Prikazska M, Keleova A, (2003) Changes in acute phase proteins after anti-tumor necrosis factor antibody (infliximab) treatment in patients with Crohn's disease. Physiol Res 52: 89-93.
35. Sallenave JM, (2000) The role of secretory leukocyte proteinase inhibitor and elafin (elastase-specific inhibitor/skin-derived antileukoprotease) as alarm antiproteinases in inflammatory lung disease. Respir Res 1: 87-92.
36. Henriksen PA, Hitt M, Xing Z, Wang J, Haslett C, et al. (2004) Adenoviral gene delivery of elafin and secretory leukocyte protease inhibitor attenuates NF-kappa B-dependent inflammatory responses of human endothelial cells and macrophages to atherogenic stimuli. J Immunol 172: 4535-4544.
37. Thomas SR, Stocker R, (1999) Redox reactions related to indoleamine 2,3-dioxygenase and tryptophan metabolism along the kynurenine pathway. Redox Rep 4: 199-220.
38. Belladonna ML, Grohmann U, Guidetti P, Volpi C, Bianchi R, et al. (2006) Kynurenine pathway enzymes in dendritic cells initiate tolerogenesis in the absence of functional IDO. J Immunol 177: 130-137.
39. Kostopanagiotou G, Avgerinos E, Costopanagiotou C, Arkadopoulos N, Andreadou I, et al. (2008) Acute lung injury in a rat model of intestinal ischemia-reperfusion: the potential time depended role of phospholipases A(2). J Surg Res 147: 108-116.
40. Franco R, Pacheco R, Gatell JM, Gallart T, Lluis C, (2007) Enzymatic and extraenzymatic role of adenosine deaminase 1 in T-cell-dendritic cell contacts and in alterations of the immune function. Crit Rev Immunol 27: 495-509.
41. Fischer J, West J, Agochukwu N, Suire C, Hale-Donze H, (2007) Induction of host chemotactic response by Encephalitozoon spp. Infect Immun 75: 1619-1625.
42. Castellino F, Huang AY, Altan-Bonnet G, Stoll S, Scheinecker C, et al. (2006) Chemokines enhance immunity by guiding naive CD8+ T cells to sites of CD4+ T cell-dendritic cell interaction. Nature 440: 890-895.
43. McKinney C, Merriman ME, Chapman PT, Gow PJ, Harrison AA, et al. (2008) Evidence for an influence of chemokine ligand 3-like 1 (CCL3L1) gene copy number on susceptibility to rheumatoid arthritis. Ann Rheum Dis 67: 409-413.
44. Bertini R, Luini W, Sozzani S, Bottazzi B, Ruggiero P, et al. (1995) Identification of MIP-1 alpha/LD78 as a monocyte chemoattractant released by the HTLV-I-transformed cell line MT4. AIDS Res Hum Retroviruses 11: 155-160.
45. Zlotnik A, Yoshie O, (2000) Chemokines: a new classification system and their role in immunity. Immunity 12: 121-127.
46. Ramadas RA, Ewart SL, Medoff BD, Levine AM, (2011) Interleukin-1 family member 9 stimulates chemokine production and neutrophil influx in mouse lungs. Am J Respir Cell Mol Biol 44: 134-145.
47. Cavaillon JM, (1994) Cytokines and macrophages. Biomed Pharmacother 48: 445-453.
48. Atzeni F, Sarzi-Puttini P, (2009) Anti-cytokine antibodies for rheumatic diseases. Curr Opin Investig Drugs 10: 1204-1211.
49. Mookherjee N, Brown KL, Bowdish DM, Doria S, Falsafi R, et al. (2006) Modulation of the TLR-mediated inflammatory response by the endogenous human host defense peptide LL-37. J Immunol 176: 2455-2464.
50. Saban R, D'Andrea MR, Andrade-Gordon P, Derian CK, Dozmorov I, et al. (2007) Regulatory network of inflammation downstream of proteinase-activated receptors. BMC Physiol 7: 3-17.
51. Chen LC, Chen CC, Liang Y, Tsang NM, Chang YS, et al. (2011) A novel role for TNFAIP2: its correlation with invasion and metastasis in nasopharyngeal carcinoma. Mod Pathol 24: 175-184.
52. Liu H, Chen A, Guo F, Yuan L, (2010) A short-hairpin RNA targeting osteopontin downregulates MMP-2 and MMP-9 expressions in prostate cancer PC-3 cells. Cancer Lett 295: 27-37.
53. Robertson BW, Bonsal L, Chellaiah MA, (2010) Regulation of Erk1/2 activation by osteopontin in PC3 human prostate cancer cells. Mol Cancer 9: 260-269.
54. Delimpoura V, Bakakos P, Tseliou E, Bessa V, Hillas G, et al. (2010) Increased levels of osteopontin in sputum supernatant in severe refractory asthma. Thorax 65: 782-786.
55. Nau GJ, Chupp GL, Emile JF, Jouanguy E, Berman JS, et al. (2000) Osteopontin expression correlates with clinical outcome in patients with mycobacterial infection. Am J Pathol 157: 37-42.
56. Chang IF, Hsiao HY, (2005) Induction of RhoGAP and pathological changes characteristic of Alzheimer's disease by UAHFEMF discharge in rat brain. Curr Alzheimer Res 2: 559-569.
57. Festen EA, Goyette P, Green T, Boucher G, Beauchamp C, et al. (2011) A meta-analysis of genome-wide association scans identifies IL18RAP, PTPN2, TAGAP, and PUS10 as shared risk loci for Crohn's disease and celiac disease. PLoS Genet 7: e1001283.
58. Eyre S, Hinks A, Bowes J, Flynn E, Martin P, et al. (2010) Overlapping genetic susceptibility variants between three autoimmune disorders: rheumatoid arthritis, type 1 diabetes and coeliac disease. Arthritis Res Ther 12: R175-R180.
59. Monteiro RC, Van De Winkel JG, (2003) IgA Fc receptors. Annu Rev Immunol 21: 177-204.
60. Knowles HJ, te Poele RH, Workman P, Harris AL, (2006) Niacin induces PPARgamma expression and transcriptional activation in macrophages via HM74 and HM74a-mediated induction of prostaglandin synthesis pathways. Biochem Pharmacol 71: 646-656.
61. Choudhary D, Jansson I, Stoilov I, Sarfarazi M, Schenkman JB, (2004) Metabolism of retinoids and arachidonic acid by human and mouse cytochrome P450 1b1. Drug Metab Dispos 32: 840-847.
62. Birnbaumer M, (2000) Vasopressin receptors. Trends Endocrinol Metab 11: 406-410.
63. Wang XJ, Dyson MT, Mondillo C, Patrignani Z, Pignataro O, et al. (2002) Interaction between arachidonic acid and cAMP signaling pathways enhances steroidogenesis and StAR gene expression in MA-10 Leydig tumor cells. Mol Cell Endocrinol 188: 55-63.
64. Williams JP, Weiser MR, Pechet TT, Kobzik L, Moore FD Jr, et al. (1997) alpha 1-Acid glycoprotein reduces local and remote injuries after intestinal ischemia in the rat. Am J Physiol 273: G1031-G1035.
65. Sallenave JM, Cunningham GA, James RM, McLachlan G, Haslett C, (2003) Regulation of pulmonary and systemic bacterial lipopolysaccharide responses in transgenic mice expressing human elafin. Infect Immun 71: 3766-3774.
66. Moilanen M, Sorsa T, Stenman M, Nyberg P, Lindy O, et al. (2003) Tumor-associated trypsinogen-2 (trypsinogen-2) activates procollagenases (MMP-1,-8,-13) and stromelysin-1 (MMP-3) and degrades type I collagen. Biochemistry 42: 5414-5420.
67. Kosaka T, Yoshino J, Inui K, Wakabayashi T, Kobayashi T, et al. (2009) Involvement of NAD(P)H:quinone oxidoreductase 1 and superoxide dismutase polymorphisms in ulcerative colitis. DNA Cell Biol 28: 625-631.
68. Gao B, Flores SC, Leff JA, Bose SK, McCord JM, (2003) Synthesis and anti-inflammatory activity of a chimeric recombinant superoxide dismutase: SOD2/3. Am J Physiol Lung Cell Mol Physiol 284: L917-L925.
69. Subramaniam M, Hawse JR, Rajamannan NM, Ingle JN, Spelsberg TC, (2010) Functional role of KLF10 in multiple disease processes. Biofactors 36: 8-18.
70. An H, Chandra V, Piraino B, Borges L, Geczy C, et al. (2010) Soluble LILRA3, a potential natural antiinflammatory protein, is increased in patients with rheumatoid arthritis and is tightly regulated by interleukin 10, tumor necrosis factor-alpha, and interferon-gamma. J Rheumatol 37: 1596-1606.
71. Singh AK, Stock P, Akbari O, (2011) Role of PD-L1 and PD-L2 in allergic diseases and asthma. Allergy 66: 155-162.
72. Kelly LM, Englmeier U, Lafon I, Sieweke MH, Graf T, (2000) MafB is an inducer of monocytic differentiation. EMBO J 19: 1987-1997.
73. Kim H, Seed B, (2010) The transcription factor MafB antagonizes antiviral responses by blocking recruitment of coactivators to the transcription factor IRF3. Nat Immunol 11: 743-750.